Fecal fusobacterium nucleatum for detecting colorectal cancer: a systematic review and meta-analysis - PubMed (original) (raw)
. 2018 Jul 1:1724600818781301.
doi: 10.1177/1724600818781301. Online ahead of print.
Affiliations
- PMID: 29968498
- DOI: 10.1177/1724600818781301
Free article
Fecal fusobacterium nucleatum for detecting colorectal cancer: a systematic review and meta-analysis
Qian Huang et al. Int J Biol Markers. 2018.
Free article
Abstract
Objective: The purpose of this systematic review and meta-analysis was to evaluate the efficacy of fecal Fusobacterium nucleatum ( Fn) for detecting colorectal cancer. It is the first systematic review and meta-analysis to focus exclusively on fecal Fn for colorectal cancer.
Materials and methods: Comprehensive searches of several databases before January 2018 were conducted. Fecal Fn for detecting colorectal cancer was evaluated via pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the curve. Heterogeneity was explored using meta-regression and subgroup analyses. The publication bias and the overall quality of evidence were also analyzed.
Results: Our analysis included six papers containing seven case-control studies in the systematic review and meta-analysis. Overall sensitivity and specificity were 0.68 (95% confidence interval (CI) 0.64, 0.72) and 0.78 (95% CI 0.75, 0.81), respectively. The positive likelihood ratio and negative likelihood ratio in detecting colorectal cancer were 2.87 (95% CI 1.62, 5.10) and 0.40 (95% CI 0.30, 0.54) respectively. The diagnostic odds ratio (OR) was 8.75 (95% CI 4.86, 15.78) and the area under the curve was 0.80. A subgroup analysis showed that in Asia, the colorectal cancer sample size ⩾50 had higher specificity (specificity 0.85, 95% CI 0.80, 0.88). No publication bias existed. The GRADEpro showed a moderate level of the available evidence.
Conclusions: Compared to other examinations, the fecal Fn test seems a good choice for detecting colorectal cancer. It also has better diagnostic performance in Asians. However, more clinical trials with large sample sizes and strict randomization are needed to further verify the evidence.
Keywords: Fecal marker; Fusobacterium nucleatum; colorectal cancer; diagnostic performance; meta-analysis.
Similar articles
- Diagnostic Performance of Intestinal Fusobacterium nucleatum in Colorectal Cancer: A Meta-Analysis.
Peng BJ, Cao CY, Li W, Zhou YJ, Zhang Y, Nie YQ, Cao YW, Li YY. Peng BJ, et al. Chin Med J (Engl). 2018 Jun 5;131(11):1349-1356. doi: 10.4103/0366-6999.232814. Chin Med J (Engl). 2018. PMID: 29786050 Free PMC article. - Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P. Crider K, et al. Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article. - Fecal Fusobacterium nucleatum for the diagnosis of colorectal tumor: A systematic review and meta-analysis.
Zhang X, Zhu X, Cao Y, Fang JY, Hong J, Chen H. Zhang X, et al. Cancer Med. 2019 Feb;8(2):480-491. doi: 10.1002/cam4.1850. Epub 2019 Jan 12. Cancer Med. 2019. PMID: 30636375 Free PMC article. - Diagnostic test accuracy of nutritional tools used to identify undernutrition in patients with colorectal cancer: a systematic review.
Håkonsen SJ, Pedersen PU, Bath-Hextall F, Kirkpatrick P. Håkonsen SJ, et al. JBI Database System Rev Implement Rep. 2015 May 15;13(4):141-87. doi: 10.11124/jbisrir-2015-1673. JBI Database System Rev Implement Rep. 2015. PMID: 26447079 Review. - Clinicopathological differences of high Fusobacterium nucleatum levels in colorectal cancer: A review and meta-analysis.
Wang Y, Wen Y, Wang J, Lai X, Xu Y, Zhang X, Zhu X, Ruan C, Huang Y. Wang Y, et al. Front Microbiol. 2022 Nov 4;13:945463. doi: 10.3389/fmicb.2022.945463. eCollection 2022. Front Microbiol. 2022. PMID: 36406461 Free PMC article. Review.
Cited by
- Detection of Fusobaterium nucleatum in feces and colorectal mucosa as a risk factor for colorectal cancer: a systematic review and meta-analysis.
Janati AI, Karp I, Laprise C, Sabri H, Emami E. Janati AI, et al. Syst Rev. 2020 Dec 3;9(1):276. doi: 10.1186/s13643-020-01526-z. Syst Rev. 2020. PMID: 33272322 Free PMC article. - Exploring the interplay between Fusobacterium nucleatum with the expression of microRNA, and inflammatory mediators in colorectal cancer.
Bostanghadiri N, Razavi S, Shariati A, Talebi M, Mirkalantari S, Emami Razavi A, Darban-Sarokhalil D. Bostanghadiri N, et al. Front Microbiol. 2023 Nov 23;14:1302719. doi: 10.3389/fmicb.2023.1302719. eCollection 2023. Front Microbiol. 2023. PMID: 38075864 Free PMC article. - Microbiome Analysis of More Than 2,000 NHS Bowel Cancer Screening Programme Samples Shows the Potential to Improve Screening Accuracy.
Young C, Wood HM, Fuentes Balaguer A, Bottomley D, Gallop N, Wilkinson L, Benton SC, Brealey M, John C, Burtonwood C, Thompson KN, Yan Y, Barrett JH, Morris EJA, Huttenhower C, Quirke P. Young C, et al. Clin Cancer Res. 2021 Apr 15;27(8):2246-2254. doi: 10.1158/1078-0432.CCR-20-3807. Epub 2021 Mar 3. Clin Cancer Res. 2021. PMID: 33658300 Free PMC article. - Fusobacterium nucleatum: a novel immune modulator in breast cancer?
Little A, Tangney M, Tunney MM, Buckley NE. Little A, et al. Expert Rev Mol Med. 2023 Apr 3;25:e15. doi: 10.1017/erm.2023.9. Expert Rev Mol Med. 2023. PMID: 37009688 Free PMC article. Review. - Fusobacterium nucleatum and cancer.
Alon-Maimon T, Mandelboim O, Bachrach G. Alon-Maimon T, et al. Periodontol 2000. 2022 Jun;89(1):166-180. doi: 10.1111/prd.12426. Epub 2022 Mar 4. Periodontol 2000. 2022. PMID: 35244982 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous